Abner Antonio Murray Highlighted JCO Study on Triplet Therapy for NPM1m/KMT2Ar AML
Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post on X:
“Huge congratulations to Joshua Zeidner on a stellar European Hematology Association presentation + first-author in JCO publication!
The Aza/Ven/Revumenib triplet in newly diagnosed older/unfit NPM1m or KMT2Ar AML delivered:
– ORR 88% | CRc 81% | CR 67%
– 100% MRD-negative by flow
– 0% refractory disease
– Well tolerated, even in ≥75yo
– [Phase III EVOLVE-2 enrolling now]Incredible work by Wendy Stock, Toyosi Odenike, UChicago Leukemia Program, UNC Lineberger, and the full BEAT AML team. Precision medicine in action!
Read here.”
Title: Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
Journal: JCO
Authors: Joshua F. Zeidner, Tara L. Lin, Rina Li Welkie, Emily Curran, Kristin Koenig, Wendy Stock, Yazan F. Madanat, Ronan Swords, Maria R. Baer, William Blum, Eytan M. Stein, Rebecca L. Olin, Gary Schiller, Angela Nichols, Olatoyosi Odenike, Elie Traer, Curtis Lachowiez, Vu H. Duong, Michael J. Hochman, Sheng F. Cai, Catherine Smith, Mona Stefanos, Molly Martycz, Ying Huang, Len Rosenberg, Sonja Marcus, Timothy L. Chen, Ashley O. Yocum, Brian J. Druker, Ross L. Levine, Uma Borate, John C. Byrd, Alice S. Mims
More posts featuring Abner Antonio Murray on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023